ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

PYM Phytopharm

58.00
0.00 (0.00%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Phytopharm LSE:PYM London Ordinary Share GB00BCLY7L40 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 58.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

IXICO plc European research to tackle dementia

09/03/2016 9:30am

RNS Non-Regulatory


TIDMIXI

IXICO plc

09 March 2016

European research to tackle the triple challenge of dementia, hearing and vision impairment

The combined impact of dementia, age-related hearing and vision impairment is to be investigated by a new multi-million European research consortium led by the University of Manchester.

Seven in ten Europeans over the age of 65 suffer from either sight or hearing problems and over two thirds suffer from depression or dementia. When combined together the cumulative impact of these dual or triple impairments is far greater than the individual conditions. The scale of combined sensory and cognitive problems is substantial but poorly understood.

The five year SENSE-Cog project, led by the University of Manchester, has been funded with EUR6.5m from the European Commission's Horizon 2020 research programme. The project aims to investigate this combined impact and develop new tools that could improve quality of life and optimise health and social care budgets across Europe.

Dr Iracema Leroi, an academic psychiatrist from The University of Manchester, who is the lead researcher on the project, said: "In combination these problems have a much greater effect than each one individually. Imagine if you have dementia which affects your memory or interferes with your recognition of familiar people. When you add visual impairment to that, you can understand why those affected may experience even greater cognitive difficulty or even experience altered behaviour such as agitation or hallucinations.

The burden on carers - often family members - is also increased as they are required to do much more on a daily basis and we see a greater number of these suffering from burn-out."

The project seeks to define the scale of the challenges so that authorities across the continent can allocate resources more optimally. At the same time, researchers will also develop online tests, guides and multi-lingual training manuals to help medical professionals diagnose and treat the combined problems more effectively.

Minority groups are particularly disadvantaged with respect to diagnosis and treatment of mental and sensory problems, so researchers will be seeking out people from these groups to participate in the research.

The programme will also trial an intervention of at-home support for people with dual- and triple-impairments. This will be supported by specialist sensory therapists based at Central Manchester University Hospitals NHS Foundation Trust and will focus around pragmatic solutions to support both the affected person and their carer.

Dr Piers Dawes, a University of Manchester audiologist and co-lead of the SENSE-Cog project said: "Millions of people in the UK and wider EU are affected by this combination of problems and it's only going to get more prevalent as the population ages. That's why we have to understand the scale of the problem and then equip the public, carers and health care workers with the tools they need to deal with it. If we could reduce disability due to hearing and vision impairment, there is huge potential to improve mental well-being and even delay the deterioration of dementia."

ENDS

Notes to editors

Interviews on request

Follow @UomNews on Twitter

The latest media videos are on our YouTube page

The latest news and coverage on Google+

A record of the University in the news is on our Scoop.it page

 
 The consortium for SENSE-Cog: 
 (1) THE UNIVERSITY OF MANCHESTER (UK, Coordinator) 
 (2) European University Cyprus (Cyprus) 
 (3) THE MANCHESTER METROPOLITAN UNIVERSITY 
  (UK) 
 (4) ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO 
  ATHINON (Greece) 
 (5) UNIVERSITE DE NICE SOPHIA ANTIPOLIS (France) 
 (6) UNIVERSITE DE BORDEAUX (France) 
 (7) Erasmus University Medical Center Rotterdam 
  (Netherlands) 
 (8) UNIVERSITETET I TROMSOE (Norway) 
 (9) Katholische Hochschule Freiburg gGmbH 
  (Germany) 
 (10) Dementia Pal Ltd (UK industrial partner) 
 (11) IXICO TECHNOLOGIES LIMITED (UK industrial 
  partner) 
 (12) Starkey Laboratories (US industrial partner) 
 (13) HORTECH GGMBH (Germany) 
 (14) ESSILOR INTERNATIONAL SA (Industrial 
  partner) 
 (15) GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM 
  MBH & CO KG (German project management partner, 
  SME) 
 (16) Centre Hospitalier Universitaire de Nice 
  (France) 
 (17) UNIVERSITY OF CYPRUS (Cyprus) 
 

Media enquiries to:

 
 Jamie Brown 
 Media Relations Officer 
 The University of Manchester 
 Tel: 0161 2758383 
 Mob: 07887 561318 
 Email: jamie.brown@manchester.ac.uk 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAVVLFBQXFXBBB

(END) Dow Jones Newswires

March 09, 2016 04:30 ET (09:30 GMT)

1 Year Phytopharm Chart

1 Year Phytopharm Chart

1 Month Phytopharm Chart

1 Month Phytopharm Chart